U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

Aug 10

Written By Team Rxtrospect

SCHEDULE A CALL

Team Rxtrospect

FDA grants accelerated approval to Pfizer's Elrexfio for r/r multiple myeloma

RxTROSPECT, Inc 2025 — All rights reserved. “RxTROSPECT” refers to RxTROSPECT, Inc.. RxTROSPECT, Inc. is an intelligence company offering a range of data and analytics products through its partnerships with Tableau, LLC (a subsidiary of Salesforce, Inc), and Mango Technologies, Inc. dba ClickUp.

Testimonials are specific to an individual Customer’s experience and may not be representative of all Customers. Unless otherwise indicated, Customers offering a Testimonial do not receive compensation and their statement does not present a conflict of interest.

RxTROSPECT is not affiliated with, sponsored, or endorsed by the companies listed, described, or featured on its site. Company logos or trademarks used do not imply endorsement and are the property of their respective owners.

This is a representative list of customers that work with RxTROSPECT as of January 1st, 2025. It is not known whether they approve or disapprove of our products.

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

FDA grants accelerated approval to Pfizer's Elrexfio for r/r multiple myeloma

Gavreto confirms benefit in NSCLC less than 3 years after initial accelerated approval

solutions

ABOUT US

RESOURCES